Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.
Looking for a particular Genelabs Technologies employee's phone or email?
The Genelabs Technologies annual revenue was $18 million in 2026.
Fred Driscoll is the CEO of Genelabs Technologies.
10 people are employed at Genelabs Technologies.
Genelabs Technologies is based in Redwood City, California.
The NAICS codes for Genelabs Technologies are [325, 32, 32541, 3254].
The SIC codes for Genelabs Technologies are [28, 283].